Sanofi Bolstered By China ‘Broad Market’ Expansion Strategy
This article was originally published in PharmAsia News
Executive Summary
Amid an increasingly gloomy economic outlook for emerging markets as a whole, and China in particular, Sanofi delivered jaw-dropping 33% growth in China in the last quarter. Aggressive expansion into the country’s vast low-tier market has started bearing fruit, said the company.